Beam Therapeutics Inc (NASDAQ: BEAM) is 12.18% higher on its value in year-to-date trading and has touched a low of $20.84 and a high of $49.50 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BEAM stock was last observed hovering at around $25.75 in the last trading session, with the day’s gains setting it 2.07%.
Currently trading at $27.82, the stock is 8.68% and 5.24% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.02 million and changing 8.04% at the moment leaves the stock 10.53% off its SMA200. BEAM registered 7.33% gain for a year compared to 6-month loss of 8.63%. The firm has a 50-day simple moving average (SMA 50) of $26.3678 and a 200-day simple moving average (SMA200) of $25.15295.
The stock witnessed a 9.61% gain in the last 1 month and extending the period to 3 months gives it a 21.33%, and is 7.37% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.96% over the week and 6.93% over the month.
Beam Therapeutics Inc (BEAM) has around 436 employees, a market worth around $2.30B and $349.64M in sales. Profit margin for the company is -41.07%. Distance from 52-week low is 33.49% and -43.80% from its 52-week high. The company has generated returns on investments over the last 12 months (-15.27%).
with sales reaching $16.47M over the same period.The EPS is expected to shrink by -172.38% this year, but quarterly earnings will post -86.39% year-over-year. Quarterly sales are estimated to shrink -94.79% in year-over-year returns.
329.0 institutions hold shares in Beam Therapeutics Inc (BEAM), with institutional investors hold 95.99% of the company’s shares. The shares outstanding are 82.56M, and float is at 72.58M with Short Float at 14.86%. Institutions hold 94.57% of the Float.
The top institutional shareholder in the company is FARALLON CAPITAL MANAGEMENT LLC with over 7.91 million shares valued at $185.4 million. The investor’s holdings represent 9.6857 of the BEAM Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 7.9 million shares valued at $185.11 million to account for 9.6701 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 7.63 million shares representing 9.3446 and valued at over $178.87 million, while ARK INVESTMENT MANAGEMENT LLC holds 9.3345 of the shares totaling 7.63 million with a market value of $178.68 million.
Beam Therapeutics Inc (BEAM) Insider Activity
The most recent transaction is an insider sale by Evans John M., the company’s CEO. SEC filings show that Evans John M. sold 30,000 shares of the company’s common stock on Jan 30 ’25 at a price of $26.75 per share for a total of $0.8 million. Following the sale, the insider now owns 0.91 million shares.
Still, SEC filings show that on Jan 02 ’25, Bellon Christine (Chief Legal Officer) disposed off 1,241 shares at an average price of $24.68 for $30628.0. The insider now directly holds 102,968 shares of Beam Therapeutics Inc (BEAM).
